All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
What impact does CAR T therapy have on patient quality of life?
Bookmark this article
During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Bregje Verhoeven from European Society for Blood and Marrow Transplantation, NL. We asked: What impact does CAR T therapy have on patient quality of life?
Bregje Verhoeven explains that quality of life (QoL) after CAR T therapy is yet to be elucidated as we do not have enough data yet. She talks about the importance of implementing the patient-reported outcomes into clinical trials. Bregje Verhoeven also discusses the patient treatment teams and their role in improving patient QoL and various other factors such as emotional and financial burdens that influence the patients QoL.
What impact does CAR T therapy have on patient quality of life?
More about...
Your opinion matters
1 vote - 53 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox